Summary
The kinetics of the in vitro cytotoxicity of DAB486IL-2, a genetically engineered fusion protein containing a portion of diphtheria toxin and human interleukin-2, were examined in the C91/PL cell line, which constitutively expresses IL-2 receptors. Maximal inhibition of protein synthesis was observed by 4–6 h after DAB486 IL-2 addition at a concentration of 300 ng/ml. The tissue distribution, urinary excretion, and plasma pharmacokinetics of DAB486IL-2 in the rat and its plasma pharmacokinetics in the monkey were also examined. In rats the primary site of distribution of [35S]-DAB486IL-2 outside the vasculature appears to be the liver, followed by the kidney, spleen, and lung. Persistence of radioactive material in the liver and urinary excretion of metabolic degradation products suggest that labeled protein is metabolized by hepatic tissue. Following i.v. bolus administration of DAB486IL-2, the initial serum half-life for both the rat and the monkey was approximately 5 min. The overall clearance rate of drug for the two species differed, with DAB486IL-2 being cleared from circulation 2–3 times more rapidly in the monkey. Presence of high levels of neutralizing antibodies to diphtheria toxin in the rat significantly influenced the clearance of bioactive DAB486IL-2. However, the question as to whether the presence of in vitro biological activity for the molecule is masked by the presence of antibodies cannot be clearly answered.
Similar content being viewed by others
References
Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB (1988) Interleukin-2 receptor-targeted cytotoxicity: interleukin-2 receptor-mediated action of a diphtheria toxin-related interleukin-2 fusion protein. J Exp Med 167: 612
Diamantstein T, Osawa H (1986) The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies. Immunol Rev 92: 5
Eksborg S, Ehrsson H, Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to Adriamycin. Cancer Chemother Pharmacol 10: 7
Figlin RA, Itri LM (1988) Anti-interferon antibodies: a perspective. Semin Hematol 25 [Suppl 3]: 9
Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K (1989) Cytotoxicity of interleukin-2 toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res 49: 4042
Lorberboum-Galski H, FitzGerald DJP, Chaudhary W, Adhya S, Pastan I (1988) Cytotoxic activity of an interleukin-2-Pseudomonas exotoxin chimeric protein produced inE. coli. Proc Natl Acad Sci USA 85: 1922
Paolozzi F, Zamkoff K, Doyle M, Konrad M, Bradley EC, Rudolf A, Newman N, Gullo J, Scalzo A, Poiesz B (1989) Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases. J Biol Response Mod 8: 122
Paolozzi FPO, Ehrlich GD, Bacha P, Nichols JC, Bhagavati S, Ratner L, Poiesz BJ (1990) Effect of recombinant interleukin-2-diphtheria toxin fusion protein on fresh and cultured HTLV-I-infected T-lymphocytes: inhibition of viral load as assessed by polymerase chain reaction (in press)
Popovic M, Lanze-Wanzin G, Sarin PS, Mann D, Gallo RC (1983) Transformation of human umbilical cord blood T-cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci USA 80: 5402
Poste G, Kirsh R (1983) Site-specific (targeted) drug delivery in cancer therapy. Bio/Technology 1: 869
Sands H, Loveless SE (1989) Biodistribution and pharmacokinetics of recombinant human [125I]-interleukin-2 in mice. Int J Immunopharmacol 11: 411
Shain SA, Huyot RI (1988) Antiandrogen effects in models of androgen-responsive cancer. J Steroid Biochem 31: 711
Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I (1988) Cytotoxic activity of an interleukin-6-Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Natl Acad Sci USA 85: 9738
Talmadge JE, Black PL, Tribble H, Pennington R, Bowersox O, Schneider M, Phillips H (1987) Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rH IFN-gamma and rH IL-2. Drugs Exp Clin Res 13: 327
Vitetta ES. Fulton RJ, May RD, Till M, Uhr JW (1987) Redesigning nature’s poisons to create anti-tumor reagents. Science 238: 1098
Waldmann TA (1988) Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. J Natl Cancer Inst 81: 914
Waters CA, Schimke PA, Snider CE, Itoh K, Smith KA, Nichols JC, Strom TB, Murphy JR (1990) Interleukin-2 receptor targeted cytotoxicity receptor binding requirements for productive entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur J Immunol (in press)
Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR (1987) Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1: 493
Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH (1988) Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. J Nucl Med 29: 174
Zucker DR, Murphy JR (1984) Monoclonal analysis of diphtheria toxin: I. Localization of epitope and neutralization of cytotoxicity. Mol Immunol 21: 785
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bacha, P., Forte, S., Kassam, N. et al. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models. Cancer Chemother Pharmacol 26, 409–414 (1990). https://doi.org/10.1007/BF02994090
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02994090